Fund of the Week: Dementia Discovery Fund

Overview and Investment Focus

The Dementia Discovery Fund (DDF), managed by SV Health Investors, is a transatlantic venture capital fund investing exclusively in companies developing or enabling novel therapeutics for dementia. Founded in 2015 and operating from London and Boston, DDF describes itself as the world's largest family of specialized venture capital funds focused on this therapeutic area. As of March 2026, the fund has raised more than $600 million across two vehicles, maintains a portfolio of more than 19 companies, and reports more than 50 programmes underway and 11 assets in clinical development. In May 2025, DDF closed its second fund, DDF-2, at $269 million.

Investment Thesis: DDF operates under what it describes as a dual mandate: delivering measurable patient impact and generating financial returns for its limited partners. The fund targets disease-modifying therapeutics across the full dementia spectrum — Alzheimer's disease (AD), frontotemporal dementia (FTD), Parkinson's disease dementia, ALS, Huntington's disease, and Lewy body dementia. It invests across the full spectrum of company stages, from target identification through clinical development, and pursues both external deals and internal company creation. Its geographic focus is the US, UK, and Europe.

From Public-Private Mandate to Institutional Venture Platform

DDF was established in 2015 in the context of the G8 Dementia Summit of 2013, at which G8 governments committed to advancing dementia research. The fund was structured as a public-private partnership with the UK's Department of Health and Social Care as an anchor participant, alongside a group of major pharmaceutical companies.

The first fund, DDF-1, reached a final close at £250 million in 2018. Its limited partner base included seven pharmaceutical companies — Biogen, Eli Lilly, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer, and Takeda — alongside AARP, Aegon, British Patient Capital, Bill Gates, the NFL Players Association, Quest Diagnostics, UnitedHealth Group, and the charities Alzheimer's Research UK and the UK Department of Health and Social Care.

The second fund, DDF-2, registered in November 2021, reached its $269 million final close in May 2025, exceeding its initial $250 million target. Returning cornerstone investors included AARP, the British Business Bank, and Gates Frontier. Pharmaceutical LPs Bristol Myers Squibb, Eli Lilly, and Pfizer re-committed. New investors included the Alzheimer's Association, which contributed $10 million, and British Patient Capital, which committed £25 million. Non-profits Alzheimer's Research UK and LifeArc also participated as LPs. DDF-2 had already invested in four companies at the time of the final close announcement.

Fund History and Capital Progression

DDF-2 targets a portfolio of 10 to 15 companies across the US, UK, and Europe.

Strategic Approach

Several features characterize how DDF constructs and manages its portfolio:

Disease-Area Concentration: The fund invests exclusively in dementia-related therapeutics. This allows the team to build domain expertise across neuroscience R&D, clinical trial design in neurodegeneration, and biomarker development over time.

Venture Creation Alongside Venture Investing: Approximately half of the companies in DDF's existing portfolio were built internally by the fund team, rather than backed after external founding. The team works with a network of venture partners and academic collaborators to create new entities around specific scientific hypotheses. Recent internally-created companies include Harness Therapeutics, Montara Therapeutics, Nitrase Therapeutics, Violet Therapeutics, and Sudo Biosciences.

Pharma LP Architecture: The participation of major pharmaceutical companies as limited partners — including several active in neurodegenerative disease M&A — creates structural alignment between the fund's portfolio companies and potential strategic partners and acquirers. The 2023 acquisition of Caraway Therapeutics by Merck illustrates this pathway, with Merck having been a pharma LP in DDF-1.

Non-Profit and Patient Advocacy LP Base: The inclusion of the Alzheimer's Association, Alzheimer's Research UK, and LifeArc as LPs provides access to patient communities, disease registries, and clinical networks relevant to the portfolio.

Active Board Involvement: DDF team members serve as board directors or observers at portfolio companies. Jonathan Behr currently holds board seats or observer roles at Montara Therapeutics, Nitrase Therapeutics, QurAlis, Ribometrix, Sudo Biosciences, Transposon Therapeutics, and Violet Therapeutics.

Investment Team

DDF operates as a strategy within SV Health Investors, a UK-based life sciences venture capital and growth equity firm founded in 1993. SV manages approximately $2 billion in assets under management across biotech, dementia, medtech, and healthcare growth strategies, with offices in London and Boston.

Jonathan Behr, Ph.D. (Partner, co-lead DDF): Joined SV Health Investors in 2019 with 18 years of venture and venture creation experience. Previously founding Managing Director of the T1D Fund. Prior portfolio exits include Inversago Therapeutics (acquired by Novo Nordisk), Pandion Therapeutics (acquired by Merck), and Provention Bio (acquired by Sanofi). Served as board director of Caraway Therapeutics prior to its Merck acquisition.

Christian B. Jung, Ph.D. (Partner, co-lead DDF): Co-leads DDF alongside Behr, overseeing European activities and bringing neuroscience R&D and life sciences venture experience.

Laurence Barker (Partner): Clinical development and translational expertise across the neurodegenerative disease pipeline.

In January 2026, SV Health Investors also appointed Nikola Trbovic as Managing Partner and Jamil Beg as Partner to its broader biotech team.

Portfolio — Key Companies (as of March 2026)

DDF's portfolio spans more than 19 companies across both funds. The tables below are based on publicly available information as of March 5, 2026.

Active Portfolio

Notable Exits

The Dementia Landscape in 2026

Dementia affects over 55 million people globally, with approximately 10 million new cases diagnosed each year, according to the World Health Organization. The WHO projects the global patient population will reach 82 million by 2030 and 152 million by 2050. Estimated global economic costs are projected to exceed $2.8 trillion annually by 2030.

The therapeutic landscape has evolved substantially since DDF's founding. The FDA approval of lecanemab (Leqembi, Eisai/Biogen, 2023) and donanemab (Kisunla, Eli Lilly, 2024) established the first treatments with demonstrated effects on slowing disease progression in early Alzheimer's disease. Both approvals validated the amyloid hypothesis in a narrow patient population and created a diagnostic infrastructure — blood-based amyloid and tau biomarkers, amyloid PET imaging — that is applicable to subsequent programmes across the field.

In parallel, genome-wide association studies and human genetics programmes have identified a second generation of drug targets — TREM2, progranulin, GBA, LRRK2, TMEM175, and others — that are informing the portfolios of DDF and several other specialist funds. Advances in therapeutic modalities including antisense oligonucleotides, RNA-targeting small molecules, gene therapy, and targeted protein degradation have expanded the technical options available.

The field continues to operate with high clinical-stage attrition, complex patient stratification requirements, and development timelines measured in decades for pivotal readouts.

Limited Partner Composition

DDF's LP base spans an unusually broad range of investor types, with pharmaceutical companies, government-backed institutions, patient charities, and commercial investors participating across both funds.

Context for Royalty and Structured Finance Observers

Most DDF portfolio companies remain in early-to-mid clinical development as of March 2026, and are therefore not yet at the stage where royalty monetisation transactions are typical. However, several programmes are approaching clinical inflection points — Phase 2/3 readouts or pre-commercial development — where royalty-backed financing or revenue interest structures become relevant capital options.

The Caraway Therapeutics exit to Merck for up to $610 million provides a reference point for the value range achievable in pre-Phase 2 acquisitions of DDF-created assets. QurAlis, with its February 2026 Phase 1/2 interim data and stated Phase 3 preparation timeline, represents one of the more advanced assets in the current portfolio from a clinical development standpoint.

The pharmaceutical LP structure provides a pathway for partnership transactions and potential royalty-generating licensing arrangements within the portfolio as programmes mature.

The author is not a lawyer or financial adviser. This article is not investment or legal advice. All data and analysis are based on publicly available information.